Eli Lilly and Company

Eli Lilly and Company has a documented history of using political influence to shield its pharmaceutical business practices from regulation and oversight. In 2012, the company settled with the U.S. Securities and Exchange Commission for $29.4 million to resolve Foreign Corrupt Practices Act violations, involving improper payments to foreign government officials. More recently, an analysis by Public Citizen in May 2024 revealed that Eli Lilly’s voluntary disclosures of its state-level lobbying activities were incomplete, failing to fully report its efforts to influence pharmaceutical policy across multiple states. The company’s federal lobbying expenditures remain substantial, with $2.2 million reported in the fourth quarter of 2025 alone. This pattern of significant political spending, coupled with a settled case of corrupt practices aimed at securing business advantages, demonstrates the company’s use of political channels to protect its commercial interests.